Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell Post-transplant lymphoproliferative disorder (PTLD) after Solid organ transplantation (SOT): the prospective multicentre phase II PTLD-2 trial
Open Access
- 16 August 2022
- journal article
- research article
- Published by Springer Nature in Leukemia
- Vol. 36 (10) , 2468-2478
Abstract
The prospective multicentre Phase II PTLD-2 trial (NCT02042391) tested modified risk-stratification in adult SOT recipients with CD20-positive PTLD based on principles established in the PTLD-1 trials: sequential treatment and risk-stratification. After rituximab monotherapy induction, patients in complete remission as well as those in partial remission with IPI < 3 at diagnosis (low-risk) continued with rituximab monotherapy and thus chemotherapy free. Most others (high-risk) received R-CHOP-21. Thoracic SOT recipients who progressed (very-high-risk) received alternating R-CHOP-21 and modified R-DHAOx. The primary endpoint was event-free survival (EFS) in the low-risk group. The PTLD-1 trials provided historical controls. Rituximab was applied subcutaneously. Of 60 patients enrolled, 21 were low-risk, 28 high-risk and 9 very-high-risk. Overall response was 45/48 (94%, 95% CI 83–98). 2-year Kaplan–Meier estimates of time to progression and overall survival were 78% (95% CI 65–90) and 68% (95% CI 55–80) – similar to the PTLD-1 trials. Treatment-related mortality was 4/59 (7%, 95% CI 2–17). In the low-risk group, 2-year EFS was 66% (95% CI 45–86) versus 52% in the historical comparator that received CHOP (p = 0.432). 2-year OS in the low-risk group was 100%. Results with R-CHOP-21 in high-risk patients confirmed previous results. Immunochemotherapy intensification in very-high-risk patients was disappointing.Keywords
Funding Information
- Roche
This publication has 32 references indexed in Scilit:
- Early and Late Posttransplant Lymphoproliferative Disorder After Lung Transplantation—34 Cases From the European PTLD NetworkTransplantation, 2013
- Burkitt post‐transplantation lymphoma in adult solid organ transplant recipientsCancer, 2012
- Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative diseaseHaematologica, 2007
- CHOP-21 for the treatment of post-transplant lymphoproliferative disorders following solid organ transplantationHaematologica, 2007
- Long‐term survival in post‐transplant lymphoproliferative disorders with a dose‐adjusted ACVBP regimenBritish Journal of Haematology, 2006
- Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 studyBlood, 2006
- Treatment of PTLD with Rituximab or ChemotherapyAmerican Journal of Transplantation, 2006
- Effect of Anti‐CD 20 Antibody Rituximab in Patients with Post‐Transplant Lymphoproliferative Disorder (PTLD)American Journal of Transplantation, 2005
- CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell LymphomaNew England Journal of Medicine, 2002
- A Predictive Model for Aggressive Non-Hodgkin's LymphomaNew England Journal of Medicine, 1993